Kanaph Therapeutics Inc.
A genome-driven drug developer building bispecific antibody, ADC, and small-molecule pipelines for cancer and eye disease.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2019 and listed on KOSDAQ in 2026, Kanaph Therapeutics Inc. is a drug development company that develops anticancer and ophthalmic disease treatments based on human genome-driven drug discovery technology. Its pipeline includes the bispecific antibody KNP-101 (anti-FAP/IL-12mut), the age-related macular degeneration candidate KNP-301 (C3b/VEGF), small-molecule programs KNP-502, KNP-503, and KNP-504, and the ADC candidate KNP-701 (anti-cMET/anti-EGFR), totaling 7 pipeline and platform programs. The company runs a business model of early out-licensing and co-development with domestic and overseas pharmaceutical companies at the preclinical and early clinical stages, having signed agreements with Dong-A ST, Oscotec, Yuhan, Lotte Biologics, and GC, for cumulative upfront payments of KRW 15.9 billion and total contract value of KRW 774.8 billion.
Products & technology
- KNP-101Next-generation immuno-oncology bispecific antibody targeting FAP and IL-12mut
- KNP-301Bispecific antibody targeting C3b and VEGF for age-related macular degeneration
- KNP-502Small-molecule dual EP2/EP4 inhibitor
- KNP-503Small-molecule SHP2 inhibitor
- KNP-504Small-molecule SOS1 inhibitor
- KNP-701Bispecific ADC targeting anti-cMET and anti-EGFR
R&D and key agreements
Source: DART corporate disclosureADC 플랫폼 기술 (신규 링커 및 페이로드) · ADC platform technology (novel linker and payload) co-developed with Lotte Biologics
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition